Beyond the Marketing Claim
The term "fiduciary-aligned PBM" has become common in benefits industry marketing. Virtually every PBM now claims some form of fiduciary alignment. Most of those claims do not survive scrutiny. Genuine fiduciary alignment in pharmacy benefit management has a specific structural meaning: the entity making routing decisions must have no financial interest in the outcome of those decisions. That structural requirement eliminates most of the market.
Plan sponsors evaluating PBMs for PBM fiduciary alignment need a framework that goes beyond marketing claims to the actual economics and operational structure of the arrangement. The gap between what PBMs advertise and what they deliver structurally is significant, and for a self-funded employer bearing personal fiduciary liability under ERISA, that gap carries real legal and financial consequences.
What Fiduciary Alignment Actually Means
A fiduciary must act in the interest of the plan participant, not in its own interest. For a PBM, this means routing each prescription to the lowest net cost channel regardless of which channel generates more revenue for the PBM. The test is simple: when the PBM has a choice between routing a prescription to a channel it owns and a channel it does not own, does the PBM consistently select the lowest cost option for the plan?
A PBM that owns specialty pharmacies, mail-order operations, or retail pharmacy chains has a structural conflict. It earns more when prescriptions are routed to its own channels. The three largest PBMs in the United States each own specialty pharmacies, mail-order pharmacies, and in some cases retail pharmacy chains. When these PBMs route a prescription to an affiliated pharmacy, the PBM captures both the administrative fee and the dispensing margin. When the same prescription is routed to an independent pharmacy, the PBM captures only the administrative fee. The financial incentive is clear.
No contract provision or disclosure requirement eliminates that conflict. It is structural. A PBM can contractually agree to pass through rebates, disclose spread, and provide transparent reporting. But as long as the PBM owns a dispensing channel, it has a financial reason to prefer that channel over alternatives. The only way to have a structurally fiduciary-aligned pharmacy benefit is to use a routing entity that has no ownership interest in any dispensing channel.
Five Questions to Ask Your PBM
Plan sponsors can evaluate PBM fiduciary alignment by asking five specific questions and evaluating the answers against the structural standard described above.
First, does the PBM or any corporate affiliate own or operate specialty pharmacies, mail-order pharmacies, or retail pharmacy chains? If the answer is yes, the PBM has a structural conflict of interest on every prescription that could be routed to one of those channels. The conflict exists regardless of what the contract says about fiduciary obligations.
Second, does the PBM earn more when a prescription is routed to its affiliated pharmacy versus an independent pharmacy? Request a specific comparison of the PBM's total revenue on a high-cost specialty drug when dispensed through its own specialty pharmacy versus when dispensed through an independent pharmacy. The difference is the quantified conflict of interest.
Third, does the PBM evaluate manufacturer-direct pricing programs as part of the routing decision, or do those programs sit outside the evaluation entirely? Most PBMs do not include manufacturer-direct channels in their adjudication logic because those channels bypass PBM infrastructure entirely. If manufacturer-direct pricing is lower and the PBM does not evaluate it, the routing decision is incomplete by definition.
Fourth, can the PBM provide a per-prescription record showing which channels were evaluated, what the net cost was in each channel, and why the winning channel was selected? This is the decision-level documentation test. If the PBM cannot produce this record for a specific prescription, it cannot demonstrate that the routing decision was made in the plan's interest.
Fifth, does the PBM pass through 100% of manufacturer rebates, or does it retain a portion? If it retains a portion, how is that portion calculated, and is the calculation auditable? CAA 2026 mandates 100% rebate pass-through for ERISA plans, but the mechanics of how rebates are calculated, allocated, and reported still vary significantly across PBM contracts.
A self-funded employer that receives clear, complete answers to all five questions has a foundation for evaluating PBM fiduciary alignment on the facts. An employer that receives vague, partial, or evasive answers has learned something equally valuable about the arrangement.
Why Disclosure Alone Is Not Fiduciary Alignment
CAA 2026 mandates significant PBM compensation disclosure. These are important reforms that give plan sponsors visibility they did not previously have. But disclosure does not eliminate conflicts of interest. It makes them visible.
A PBM that discloses that it earned $50 per prescription by routing to its own specialty pharmacy is more transparent than one that does not disclose it. But it is still routing to its own pharmacy. The plan sponsor now knows about the conflict but cannot change the underlying routing decision after it has been made. The prescription was already filled. The member already received the medication. The only thing the employer can do with the disclosure is decide whether to continue the arrangement going forward.
Transparency is a necessary condition for fiduciary oversight. It is not a sufficient condition. Genuine PBM fiduciary alignment requires that the conflict not exist in the first place, not that it be disclosed after the fact. For plan sponsors who have been told that a transparent PBM is a fiduciary-aligned PBM, the distinction is critical.
The Independent Routing Layer
The structural solution to the PBM conflict of interest is an independent routing layer that sits between the prescription and the fulfillment channel. An independent routing entity evaluates all available channels in real time, including PBM channels, manufacturer-direct programs, and independent pharmacy, applies the plan's program rules, and routes to the lowest net cost channel with no financial stake in which channel wins.
The plan's existing PBM continues to administer the majority of the formulary. The independent routing layer handles only the targeted high-cost drugs where channel conflict is most likely to affect the routing decision. For a typical self-funded employer, this means GLP-1 medications, specialty drugs, and other high-cost categories where the spread between channels can be hundreds of dollars per prescription per month.
This is not a PBM replacement. It is a verification layer that makes the plan's pharmacy benefit decisions independently auditable. Every routing decision processed through the independent layer produces decision-level documentation showing the channels evaluated, the costs compared, the rules applied, and the rationale for the selection. That documentation is what transforms a fiduciary claim from a marketing statement into an evidentiary record.
What Employers Should Do Now
Plan sponsors can take three practical steps to evaluate and strengthen the fiduciary alignment of their pharmacy benefit.
First, request the five-question answers from your current PBM in writing. Send the questions formally and ask for a written response. The answers, or the refusal to provide them, tell you a great deal about the structural alignment of the arrangement. Document the request and the response as part of your fiduciary record.
Second, review your PBM contract for exclusivity provisions that require all prescriptions to be routed through the PBM's network. Assess whether those provisions are serving the plan's interest or protecting the PBM's revenue. If the contract prevents the plan from evaluating lower-cost channels for high-cost drugs, the exclusivity provision may itself be a fiduciary concern. Review this with legal counsel before the next contract renewal.
Third, evaluate whether an independent routing layer for high-cost drugs would improve both the economics and the fiduciary defensibility of the pharmacy benefit. The evaluation should include a cost comparison on the plan's actual high-cost drug utilization, an assessment of the operational requirements, and a review of how the independent layer integrates with the existing PBM and TPA.
These three steps do not require replacing the PBM. They do not require a wholesale change to the pharmacy benefit. They require the self-funded employer to exercise the kind of active, documented oversight that ERISA's prudent expert standard demands.
A Structurally Independent Platform
ApalyRx is a pharmacy-licensed platform with no ownership in any dispensing channel, meeting all five Drug Benefit Integrity requirements for structural independence. For plan sponsors evaluating the fiduciary alignment of their pharmacy benefit, read the full Drug Benefit Integrity standard. For a detailed view of how independent routing works inside the employer benefit, see how the platform works.